PapersFlow Research Brief
Hematological disorders and diagnostics
Research Guide
What is Hematological disorders and diagnostics?
Hematological disorders and diagnostics refers to the clinical evaluation, classification systems, and diagnostic tools such as FDG PET/CT imaging, bone marrow biopsy, and algorithms for identifying causes of fever of unknown origin (FUO), pancytopenia, inflammation, and hematological malignancies including myeloid neoplasms and acute leukemias.
This field encompasses 76,347 published works focused on diagnostic approaches to FUO, emphasizing FDG PET/CT, bone marrow biopsy, and pancytopenia evaluation. Studies include prospective trials, meta-analyses, and systematic reviews on etiological profiles and clinical algorithms for inflammation and hematological malignancies. Key contributions involve iterative World Health Organization classifications refining tumor identification in hematopoietic and lymphoid tissues.
Topic Hierarchy
Research Sub-Topics
WHO Classification of Haematopoietic Neoplasms
This sub-topic updates morphological, genetic, and immunophenotypic criteria for lymphoid and myeloid malignancies. Researchers validate classifications through clinico-pathologic correlations and molecular studies.
Bone Marrow Biopsy in Hematological Diagnosis
This sub-topic evaluates biopsy yield for pancytopenia, malignancies, and infections, optimizing techniques and indications. Researchers compare aspiration, trephine, and molecular adjuncts.
FDG PET/CT in Hematological Malignancies
This sub-topic assesses PET/CT sensitivity for lymphoma staging, response evaluation, and FUO in hematology. Researchers conduct meta-analyses on Deauville criteria and novel tracers.
Myelodysplastic Syndromes Prognostication
This sub-topic refines IPSS-R and molecular scores incorporating cytogenetics, mutations, and flow cytometry. Researchers validate risk models for treatment stratification.
Acute Myeloid Leukemia Classification
This sub-topic integrates genomics, ELN criteria, and measurable residual disease for AML subtyping. Researchers study risk-adapted therapies and relapse predictors.
Why It Matters
Hematological disorders and diagnostics directly inform patient management in emergency medicine by enabling precise identification of malignancies like acute leukemias and myeloid neoplasms, which guide treatment decisions and prognosis. For instance, the Revised International Prognostic Scoring System for Myelodysplastic Syndromes by Greenberg et al. (2012) refined the IPSS using data from international databases, improving risk assessment for untreated adult MDS patients and supporting therapeutic choices. Classifications such as "The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia" by Arber et al. (2016) incorporated biomarkers to distinguish unique disease entities, aiding targeted therapies in clinical practice. Bone marrow biopsy, highlighted in diagnostic algorithms for FUO and pancytopenia, facilitates early detection of underlying hematological malignancies, reducing diagnostic delays in hospital settings.
Reading Guide
Where to Start
"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues" by Swerdlow (2017) serves as the foundational reference, offering a comprehensive standardized framework for tumor categorization essential before exploring revisions or specific diagnostics.
Key Papers Explained
"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues" by Swerdlow (2017) establishes the baseline, which Vardiman et al. (2009) revise in "The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia" to incorporate hematopathology updates; Arber et al. (2016) build further in "The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia" with biomarkers; Greenberg et al. (2012) apply this in "Revised International Prognostic Scoring System for Myelodysplastic Syndromes" for prognosis; Bennett et al. (1976) provide historical context via "Proposals for the Classification of the Acute Leukaemias French‐American‐British (FAB) Co‐operative Group."
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Recent emphasis remains on FDG PET/CT and bone marrow biopsy integration into FUO algorithms, with prospective studies evaluating pancytopenia etiologies; no new preprints available, sustaining focus on WHO refinements like Arber et al. (2016) for myeloid diagnostics.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | WHO Classification of Tumours of Haematopoietic and Lymphoid T... | 2017 | Medical Entomology and... | 13.0K | ✓ |
| 2 | The 2016 revision to the World Health Organization classificat... | 2016 | Blood | 10.0K | ✓ |
| 3 | Proposals for the Classification of the Acute Leukaemias F<scp... | 1976 | British Journal of Hae... | 5.6K | ✕ |
| 4 | The 2008 revision of the World Health Organization (WHO) class... | 2009 | Blood | 4.4K | ✓ |
| 5 | Mesenchymal and haematopoietic stem cells form a unique bone m... | 2010 | Nature | 3.3K | ✕ |
| 6 | WHO Classification: Tumours of the Haematopoietic and Lymphoid... | 2015 | — | 3.3K | ✕ |
| 7 | Revised International Prognostic Scoring System for Myelodyspl... | 2012 | Blood | 3.0K | ✓ |
| 8 | Proposed Revised Criteria for the Classification of Acute Myel... | 1985 | Annals of Internal Med... | 2.9K | ✕ |
| 9 | Bone Marrow Transplant | 1990 | Nursing Clinics of Nor... | 2.7K | ✕ |
| 10 | Global, Regional, and National Cancer Incidence, Mortality, Ye... | 2019 | JAMA Oncology | 2.6K | ✓ |
Frequently Asked Questions
What is the WHO classification of haematopoietic and lymphoid tumours?
The WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues by Swerdlow (2017) provides a standardized system for identifying and categorizing tumors in these tissues. It serves as a reference for clinical trials and cell-surface marker studies. The classification has been iteratively updated to incorporate advances in biomarkers.
How has the WHO classification of myeloid neoplasms evolved?
"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia" by Vardiman et al. (2009) updated the prior edition through collaboration with hematopathology societies. It introduced rationale for changes in tumor categorization. "The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia" by Arber et al. (2016) further advanced this by integrating new biomarkers for myeloid neoplasms and acute leukemias.
What diagnostic tools are used for fever of unknown origin?
FDG PET/CT imaging and bone marrow biopsy form core components of diagnostic algorithms for FUO, particularly in cases linked to inflammation and hematological malignancies. These tools aid in evaluating pancytopenia and etiological profiles. Prospective studies and meta-analyses validate their role in clinical evaluation.
What is the FAB classification for acute leukaemias?
"Proposals for the Classification of the Acute Leukaemias French‐American‐British (FAB) Co‐operative Group" by Bennett et al. (1976) established a uniform nomenclature system for acute leukaemias. It enabled accurate recording of case distributions in clinical trials. The system provided a reference for emerging cell-surface markers.
How is prognosis assessed in myelodysplastic syndromes?
"Revised International Prognostic Scoring System for Myelodysplastic Syndromes" by Greenberg et al. (2012) refined the original IPSS using coalesced international patient databases. It offers a standard for assessing prognosis in primary untreated adult MDS patients. The revision assembles larger datasets for improved accuracy.
What role does bone marrow play in haematopoietic disorders?
"Mesenchymal and haematopoietic stem cells form a unique bone marrow niche" by Méndez‐Ferrer et al. (2010) describes the bone marrow niche formed by mesenchymal and haematopoietic stem cells. This niche supports stem cell function in haematopoiesis. It relates to diagnostics involving bone marrow biopsy for disorders like pancytopenia.
Open Research Questions
- ? How can FDG PET/CT specificity be enhanced for distinguishing inflammatory causes from hematological malignancies in FUO?
- ? What biomarkers will refine the next WHO classification update beyond 2016 revisions for myeloid neoplasms?
- ? How does the bone marrow niche influence diagnostic yield of biopsies in pancytopenia patients?
- ? Which etiological profiles predominate in FUO cases unresponsive to initial algorithms?
- ? Can revised prognostic scoring systems like IPSS be adapted for real-time emergency diagnostics?
Recent Trends
The field maintains 76,347 works with sustained emphasis on WHO classifications, as evidenced by high citations for Swerdlow at 13,029 and Arber et al. (2016) at 9,991, reflecting ongoing reliance on 2016 myeloid neoplasm revisions amid absent recent preprints or news.
2017Research Hematological disorders and diagnostics with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Hematological disorders and diagnostics with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers